<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03445871</url>
  </required_header>
  <id_info>
    <org_study_id>1708155</org_study_id>
    <secondary_id>2017-004348-39</secondary_id>
    <nct_id>NCT03445871</nct_id>
  </id_info>
  <brief_title>Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate</brief_title>
  <acronym>POLYGLU</acronym>
  <official_title>Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Methotrexate (MTX) is the first-line treatment of rheumatoid arthritis (RA). In case of MTX
      failure, it is discussed to start a Biologic Disease-modifying Antirheumatic Drug (bDMARDs)
      according to the latest European recommendations of the EULAR. Before to add a Biologic
      Disease-modifying Antirheumatic Drug (bDMARDs), an objective estimation of MTX impregnation
      could be carried out by MTX polyglutamates (MTX-PG). In rheumatoid arthritis patients with
      active disease estimated by DAS28 (Disease activity Score 28)&gt; 3.2 insufficiently controlled
      by MTX subcutaneously and patients in remission obtained with a DAS 28 &lt;2.6 with methotrexate
      prescribed since more than 6 months at stable dose for at least 3 months, a concentration of
      MTX-PG will be achieved.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The assumption is the association between low methotrexate erythrocyte polyglutamate and low
      clinical response in rheumatoid arthritis patients treated with subcutaneous injectable
      methotrexate. Adherence to MTX will be assessed by the Compliance Questionnaire Rheumatology
      (CQR). Measurement of this adherence could optimize MTX treatment prior to the use of
      biotherapy which is costly with a lower infectious tolerance.

      Correlation between its concentration and compliance assessed by CQR questionnaire will be
      tested.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTX-PG concentration</measure>
    <time_frame>Hour 1</time_frame>
    <description>To compare MTX-PG concentration in patients with active rheumatoid arthritis and patients with rheumatoid arthritis in remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>different metabolites dosing of MTX-PG</measure>
    <time_frame>Hour 1</time_frame>
    <description>Analysis of different metabolites dosing of MTX-PG by High-performance liquid chromatography technical</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CQR score</measure>
    <time_frame>Hour 1</time_frame>
    <description>Analysis of CQR score response</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Patients with active rheumatoid arthritis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with active rheumatoid arthritis will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with rheumatoid arthritis into remission</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients with rheumatoid arthritis into remission will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Blood samples will be collected for measuring PG-MTX blood concentration.</description>
    <arm_group_label>Patients with active rheumatoid arthritis</arm_group_label>
    <arm_group_label>Patients with rheumatoid arthritis into remission</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CRQ</intervention_name>
    <description>Compliance Rheumatology Questionnaire (CQR) is a self-administered questionnaire for to evaluate therapeutic observance during rheumatoid arthritis.</description>
    <arm_group_label>Patients with active rheumatoid arthritis</arm_group_label>
    <arm_group_label>Patients with rheumatoid arthritis into remission</arm_group_label>
    <other_name>Compliance Rheumatology Questionnaire</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years and have social security affiliation.

          -  Patients followed in the Rheumatology Department at the hospital of St Etienne.

          -  Patients with rheumatoid arthritis and :

               -  Either Rheumatoid arthritis patients in remission (DAS 28&lt;2.6) with MTX treatment
                  for at least 6months, and with a stable dose for 3months.

               -  Or patients with a High Disease Activity Rheumatoid Arthritis activity (DAS
                  28&gt;3.2) with MTX treatment (≥ 15 mg/weeks), taking MTX treatment for at least
                  6months with a stable subcutaneous weekly MTX injection (≥ 15 mg/weeks) treatment
                  during the previous 3 months.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Patients treated with another conventional synthetic Disease Modifying Anti-Rheumatic
             Drugs (csDMARD)

          -  Another diagnostic than rheumatoid arthritis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hubert MAROTTE, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hubert MAROTTE, MD PhD</last_name>
    <phone>(0)477127643</phone>
    <phone_ext>+33</phone_ext>
    <email>hubert.marotte@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florence RANCON, CRA</last_name>
    <phone>(0)477120284</phone>
    <phone_ext>+33</phone_ext>
    <email>florence.rancon@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Saint Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2018</study_first_submitted>
  <study_first_submitted_qc>February 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Erythrocyte polyglutamate</keyword>
  <keyword>Compliance Questionnaire Rheumatology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

